

Alberto Horenstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2577574/publications.pdf>

Version: 2024-02-01

36
papers

2,888
citations

257450

24
h-index

361022

35
g-index

36
all docs

36
docs citations

36
times ranked

3668
citing authors

#	ARTICLE	IF	CITATIONS
1	CD73/Adenosine Pathway Involvement in the Interaction of Non-Small Cell Lung Cancer Stem Cells and Bone Cells in the Pre-Metastatic Niche. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5126.	4.1	9
2	Molecular dynamics of targeting CD38 in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 581-591.	2.5	16
3	CD38 in the age of COVID-19: a medical perspective. <i>Physiological Reviews</i> , 2021, 101, 1457-1486.	28.8	32
4	The Circular Life of Human CD38: From Basic Science to Clinics and Back. <i>Molecules</i> , 2020, 25, 4844.	3.8	17
5	CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy. <i>Frontiers in Immunology</i> , 2019, 10, 760.	4.8	56
6	Microvesicles expressing adenosinergic ectoenzymes and their potential role in modulating bone marrow infiltration by neuroblastoma cells. <i>Oncolmmunology</i> , 2019, 8, e1574198.	4.6	29
7	Ectonucleotidase Expression on Human Amnion Epithelial Cells: Adenosinergic Pathways and Dichotomic Effects on Immune Effector Cell Populations. <i>Journal of Immunology</i> , 2019, 202, 724-735.	0.8	13
8	Functional insights into nucleotide-metabolizing ectoenzymes expressed by bone marrow-resident cells in patients with multiple myeloma. <i>Immunology Letters</i> , 2019, 205, 40-50.	2.5	11
9	Canonical and non-canonical adenosinergic pathways. <i>Immunology Letters</i> , 2019, 205, 25-30.	2.5	48
10	Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD ⁺ . <i>Oncolmmunology</i> , 2018, 7, e1458809.	4.6	59
11	CD38 modulates respiratory syncytial virus-driven proinflammatory processes in human monocyte-derived dendritic cells. <i>Immunology</i> , 2018, 154, 122-131.	4.4	28
12	CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 2722.	4.8	124
13	The Role of Extracellular Adenosine Generation in the Development of Autoimmune Diseases. <i>Mediators of Inflammation</i> , 2018, 2018, 1-10.	3.0	38
14	Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors. <i>Frontiers in Pharmacology</i> , 2018, 9, 196.	3.5	15
15	Antibody mimicry, receptors and clinical applications. <i>Human Antibodies</i> , 2017, 25, 75-85.	1.5	15
16	Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche. <i>Frontiers in Immunology</i> , 2017, 8, 305.	4.8	52
17	Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation. <i>Oncotarget</i> , 2017, 8, 56598-56611.	1.8	52
18	Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma. <i>Molecular Medicine</i> , 2016, 22, 694-704.	4.4	81

#	ARTICLE	IF	CITATIONS
19	CD38 and Antibody Therapy: What Can Basic Science Add?. <i>Blood</i> , 2016, 128, SCI-36-SCI-36.	1.4	8
20	NAD ⁺ -Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model. <i>Cells</i> , 2015, 4, 520-537.	4.1	99
21	Unconventional, adenosine-producing suppressor T cells induced by dendritic cells exposed to BPZE1 pertussis vaccine. <i>Journal of Leukocyte Biology</i> , 2015, 98, 631-639.	3.3	14
22	CD56 ^{bright} CD16 ^{hi} NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4 ⁺ T Cell Proliferation. <i>Journal of Immunology</i> , 2015, 195, 965-972.	0.8	111
23	Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. <i>Annals of the New York Academy of Sciences</i> , 2015, 1335, 10-22.	3.8	47
24	A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation. <i>Oncotarget</i> , 2015, 6, 25602-25618.	1.8	79
25	The ADP-ribosyl cyclases - the current evolutionary state of the ARCs. <i>Frontiers in Bioscience - Landmark</i> , 2014, 19, 986.	3.0	28
26	CD38 and bone marrow microenvironment. <i>Frontiers in Bioscience - Landmark</i> , 2014, 19, 152.	3.0	26
27	CD38 and CD157: A long journey from activation markers to multifunctional molecules. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84B, 207-217.	1.5	236
28	A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. <i>Oncolmmunology</i> , 2013, 2, e26246.	4.6	216
29	CD38 and CD157 Ectoenzymes Mark Cell Subsets in the Human Corneal Limbus. <i>Molecular Medicine</i> , 2009, 15, 76-84.	4.4	46
30	CD38 Induces Homing of Chronic Lymphocytic Leukemia Cells to the Lymphoid Organs through a Functional Interplay with CXCR4. <i>Blood</i> , 2009, 114, 2328-2328.	1.4	0
31	Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology. <i>Physiological Reviews</i> , 2008, 88, 841-886.	28.8	727
32	CD38 binding to human myeloid cells is mediated by mouse and human CD31. <i>Biochemical Journal</i> , 1998, 330, 1129-1135.	3.7	36
33	c-kit Is Expressed in Soft Tissue Sarcoma of Neuroectodermic Origin and Its Ligand Prevents Apoptosis of Neoplastic Cells. <i>Blood</i> , 1998, 91, 2397-2405.	1.4	94
34	c-kit Is Expressed in Soft Tissue Sarcoma of Neuroectodermic Origin and Its Ligand Prevents Apoptosis of Neoplastic Cells. <i>Blood</i> , 1998, 91, 2397-2405.	1.4	8
35	Human CD38 ligand. A 120-KDA protein predominantly expressed on endothelial cells. <i>Journal of Immunology</i> , 1996, 156, 727-34.	0.8	87
36	Human CD38: a glycoprotein in search of a function. <i>Trends in Immunology</i> , 1994, 15, 95-97.	7.5	331